Rapport Therapeutics (NASDAQ:RAPP) Director Ramiro Sanchez Buys 3,600 Shares of Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Director Ramiro Sanchez acquired 3,600 shares of the stock in a transaction dated Friday, October 23rd. The stock was acquired at an average cost of $27.35 per share, with a total value of $98,460.00. Following the purchase, the director owned 3,600 shares of the company’s stock, valued at approximately $98,460. This trade represents a ? increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Rapport Therapeutics Stock Performance

Shares of RAPP stock opened at $25.93 on Friday. Rapport Therapeutics, Inc. has a fifty-two week low of $23.75 and a fifty-two week high of $52.93. The company has a 50 day moving average price of $39.01 and a 200 day moving average price of $38.93. The stock has a market capitalization of $1.24 billion, a P/E ratio of -8.53 and a beta of 1.22.

Rapport Therapeutics (NASDAQ:RAPP) last released its earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). On average, research analysts forecast that Rapport Therapeutics, Inc. will post -4.08 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on RAPP. JonesTrading boosted their target price on Rapport Therapeutics from $50.00 to $82.00 and gave the stock a “buy” rating in a research note on Wednesday. TD Cowen reaffirmed a “buy” rating on shares of Rapport Therapeutics in a research report on Tuesday. Guggenheim lifted their price objective on Rapport Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday. Citigroup reissued an “outperform” rating on shares of Rapport Therapeutics in a research report on Tuesday. Finally, Raymond James Financial restated a “strong-buy” rating and set a $86.00 target price on shares of Rapport Therapeutics in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $68.36.

Hedge Funds Weigh In On Rapport Therapeutics

Several large investors have recently bought and sold shares of RAPP. AlphaCentric Advisors LLC increased its holdings in shares of Rapport Therapeutics by 6.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company’s stock valued at $201,000 after acquiring an additional 408 shares during the last quarter. Sterling Capital Management LLC raised its position in shares of Rapport Therapeutics by 597.9% during the 3rd quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock worth $33,000 after acquiring an additional 843 shares in the last quarter. KBC Group NV purchased a new stake in Rapport Therapeutics during the first quarter worth approximately $30,000. State of Wyoming purchased a new stake in Rapport Therapeutics during the second quarter worth approximately $65,000. Finally, Swiss National Bank lifted its stake in Rapport Therapeutics by 3.5% during the first quarter. Swiss National Bank now owns 56,500 shares of the company’s stock worth $1,768,000 after purchasing an additional 1,900 shares during the last quarter.

Rapport Therapeutics News Summary

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 met both Phase 2 endpoints in bipolar mania. The drug delivered statistically significant placebo-adjusted improvements in mania scores, and Rapport plans to advance it into Phase 3. Success could expand RAP-219’s opportunity beyond epilepsy and materially increase the company’s pipeline value. Rapport Therapeutics Phase 2 results
• Positive Sentiment: Analysts remain optimistic and raised price targets. JonesTrading lifted its target to $82, BTIG to $89 and Raymond James to $86, while HC Wainwright maintained a Buy rating. The reported consensus target of approximately $68.36 implies substantial upside from recent levels. Rapport Therapeutics analyst price target
• Positive Sentiment: Multiple insiders bought shares on the open market. CFO Troy Ignelzi purchased 5,500 shares, while directors Steven Paul, John Maraganore, Wendy Young, Paul Silva and Ramiro Sanchez also bought shares. The purchases totaled roughly $1.8 million based on the disclosed transactions and may signal management confidence following the clinical update. Rapport Therapeutics insider buying
• Neutral Sentiment: An analysis suggested Rapport could be significantly below estimated fair value following the Phase 2 results, but that valuation depends on successful Phase 3 development, regulatory approval and eventual commercialization.
• Negative Sentiment: Investors may have viewed the clinical win as less decisive than hoped. Reports indicated that some portions of the data only narrowly met expectations, potentially prompting profit-taking after the initial rally. Rapport bipolar mania data analysis
• Negative Sentiment: Rapport remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss missed analyst expectations, and analysts forecast a full-year loss of approximately $4.09 per share. CEO Abraham Ceesay also sold 2,210 shares, a relatively small reduction of 0.49% in his holdings, which contrasts with the broader insider buying. SEC CEO ownership filing

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.